Form 4: ResMed Director Peter C. Farrell Sells Shares Under Pre-Arranged 10b5-1 Plan

ResMed Inc. Director Peter C. Farrell reported the sale of 2,000 shares of common stock for $247.32 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Peter C. Farrell, a Director and Chairman emeritus of ResMed Inc. (RMD), reported a transaction involving the company's common stock.
• On June 4, 2025, Mr. Farrell disposed of 2,000 shares of ResMed Common Stock.
• The shares were sold at a price of $247.32 per share.
• Following this transaction, Mr. Farrell directly beneficially owns 69,218 shares of ResMed Common Stock.
• The sale was conducted under a Rule 10b5-1 plan, which was adopted on May 28, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates any strong negative signal, suggesting it's part of routine personal financial management rather than a reaction to adverse company developments.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary sale, which often suggests personal financial planning rather than a reaction to new negative company information.

Negatives

• A director's sale of shares, even under a 10b5-1 plan, reduces their direct equity stake in the company, which some investors might perceive as a slight reduction in alignment of interests.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024."
• "Peter C. Farrell, Chairman emeritus"

Industry Context

This document is an insider transaction report specific to ResMed Inc. and does not provide broader industry trends or context.

Stakeholder Impact

• Shareholders: May view the sale as a routine personal financial decision given the 10b5-1 plan, but some might still note the reduction in direct insider ownership.

Key Dates

Recommendation

Keywords

ResMed, RMD, Peter C. Farrell, insider trading, Form 4, stock sale, 10b5-1 plan, director, beneficial ownership